한글목차

세계 액체 생검 시장은 2024년에 90억 7,000만 달러에 달했습니다. 2033년에는 251억 9,000만 달러에 달할 것으로 예측되며, 예측 기간인 2025-2033년 10.7%의 연평균 복합 성장률(CAGR)을 보일 것으로 예상됩니다.

주요 요약

액체 생검은 혈액, 소변, 정액, 타액 등의 체액에서 세포 바이오마커와 분자 바이오마커를 검출하여 진단, 예후 예측, 질병 예측 정보를 제공하는 최소침습적 검사입니다. 또한, 액체 생검은 조기 암의 발견, 국소암 환자의 종양 병기 및 모니터링, 진행성 암 환자의 전이성 진행 예측, 치료 효과 모니터링을 위해 임상현장에서 활용되고 있지만, 스크리닝은 여전히 어려운 실정입니다.

시장 역학:

성장 촉진요인과 억제요인

암 유병률 증가

액체 생검 시장은 전 세계 암 발병률 증가로 인해 수요가 증가하고 있으며, 환자의 예후를 개선하기 위해 조기 발견과 실시간 모니터링이 필요해짐에 따라 수요가 증가하고 있습니다. 기존의 방법은 침습적이고 시간이 오래 걸리기 때문에 액체 생검은 비침습적인 대안이 될 수 있습니다. 액체 생검은 혈액 샘플에서 순환 종양 DNA, CTC 및 기타 바이오마커를 검출하여 조기 진단, 치료 모니터링 및 맞춤 치료 선택을 용이하게 합니다. 예를 들어, 미국암협회(ACS)는 2025년 암 통계를 발표하면서 올해 미국에서 200만 명 이상이 새로 암 진단을 받고 60만 명 이상이 암으로 사망할 것으로 추정하고 있습니다.

조사에 따르면, 2025년 미국에서 새로 암 진단을 받을 환자는 204만 1910명으로, 매일 약 5600명이 새로 암 진단을 받을 것으로 예상됩니다. 이 수치는 남성은 105만 3,250명, 여성은 98만 8,660명의 암 환자 수입니다.

표준화 및 규제 과제

세계 액체 생검 시장을 유지하는 주요 요인 중 하나는 규제 당국의 표준화와 엄격한 규칙이 없습니다는 점입니다. 액체 생검 기술은 복잡한 검사 방법을 사용하며, 스크리닝 방법이 변경되면 검사 결과가 일관되지 않을 수 있습니다. 테스트 검증, 샘플 취급, 결과의 의미 파악에 대해 일반적으로 합의된 규칙이 없기 때문에 널리 채택되기 어렵습니다.

또한, FDA 및 EMA와 같은 규제 기관은 액체 생검 검사에 대한 많은 임상적 근거를 요구하기 때문에 승인 절차에 시간이 오래 걸립니다. 이러한 문제로 인해 신제품이 시장에 출시되기까지 시간이 오래 걸리고, 중소기업이 새로운 액체 생검 옵션을 시장에 출시하는 데 어려움을 겪고 있습니다.

목차

제1장 분석 방법이및 분석 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 전략적 인사이트와 업계 전망

• 시장 리더와 선구자
  • 새로운 선구자와 주요 기업
  • 최대 판매를 자랑하는 브랜드를 확립한 리더
  • 확립된 제품을 보유한 시장 리더
• CXO 시점
• 최신 개발과 Break through
• 사례 연구/진행 중인 연구
• 규제와 상환 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 추천 전략
• 시나리오 분석 : 베스트 케이스/베이스 케이스/워스트 케이스 예측
• 가격 분석과 가격 시장 역학
• KOL(Key Opinion Leader)

제6장 제품 유형별

• 키트 및 시약
• 장치
• 서비스

제7장 순환 바이오마커별

• 순환종양 세포
• 순환종양 DNA(ctDNA)
• 유리 DNA(cfDNA)
• 세포외소포

제8장 용도별

• 암 용도
• 암 용도 이외

제9장 기술별

• Multi-gene-parallel Analysis (NGS)*
• Single Gene Analysis (PCR Microarrays)

제10장 최종사용자별

• 병원 및 개업의
• 연구센터
• 기타

제11장 지역별

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제12장 경쟁 구도

• 경쟁 시나리오
• 시장 현황 및 점유율 분석
• 인수합병(M&A) 분석

제13장 기업 개요

• Exosome Sciences Inc
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품 핵심성과지표(KPI)
    • 제품 판매 실적과 예측
    • 제품 판매량
  • 재무 개요
    • 기업 매출
    • 매출 점유율 : 지역별
    • 매출 예측
  • 주요 동향
    • 인수합병(M&A)
    • 주요 제품 개발 활동
    • 규제기관 승인 등
  • SWOT 분석
• Illumina, Inc
• Guardant Health
• Thermo Fisher Scientific Inc
• NeoGenomics Laboratories
• Qiagen
• BioChain Institute Inc
• Sysmex Europe SE
• Eurofins Genomics
• Goffin Molecular Technologies
• Similar data will be provided for each market player.
• Exact Sciences
  • 파이프라인 제품 설명
  • 제품 핵심성과지표(KPI)
  • 주요 활동
  • 시장 참여 타임라인
  • 제품 보급률
  • 판매 예측과 예측
• Tempus
• Dxcover Limited
• 각 시장 진출기업에 대해서도 같은 데이터가 제공됩니다.

제12장 부록

영문목차

The global liquid biopsy market reached US$ 9.07 billion in 2024 and is expected to reach US$ 25.19 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

Executive Summary

Liquid biopsy is a minimally invasive test that detects cellular or molecular biomarkers in body fluids like blood, urine, semen, or saliva, providing diagnostic, prognostic, or predictive disease information. Moreover, Liquid biopsy is utilized in clinical settings for early cancer detection, tumor staging and monitoring of localized cancer patients, predicting metastatic progression in advanced cancer patients, and monitoring treatment efficacy, although screening remains challenging.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Cancer

The liquid biopsy market is gaining demand due to the rising global cancer burden, which necessitates early detection and real-time monitoring for improved patient outcomes. Traditional methods are invasive and time-consuming, making liquid biopsy a non-invasive alternative. It allows for the detection of circulating tumor DNA, CTCs, and other biomarkers from blood samples, facilitating early diagnosis, treatment monitoring, and personalized therapy selection. For instance, the American Cancer Society (ACS) has revealed cancer statistics for 2025, estimating that more than 2 million new occurrences of cancer will be diagnosed in the United States this year, with over 600,000 people dying from cancer.

Researchers predict that in 2025, there will be 2,041,910 new cancer diagnoses in the United States, which equates to almost 5600 new cases every day. The figure comprises 1,053,250 cancer cases in males and 988,660 in women.

Standardization and Regulatory Challenges

One of the main things about retaining the global liquid biopsy market is the lack of standards and strict rules from regulators. Liquid biopsy technologies use complicated testing methods, and test results can be inconsistent when screening methods are changed. There aren't any generally agreed upon rules for validating tests, handling samples, and figuring out what the results mean, which makes it hard for broad adoption.

Also, regulatory bodies like the FDA and EMA need a lot of clinical support for liquid biopsy tests, which makes the approval process take longer. These problems make it take longer for new goods to reach the market and make it harder for smaller businesses to bring new liquid biopsy options to market.

Segment Analysis

The global liquid biopsy market is segmented based on product type, circulating biomarker, application, technology, end user and region.

Product Type:

Kits and reagents in product type segment is expected to dominate with highest market share

Kits and reagents play a crucial role in liquid biopsy, a minimally invasive test that analyzes body fluids, such as blood, to detect circulating tumor cells(CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). These components are essential for the extraction, purification, and analysis of the target molecules. Extraction kits, these kits are designed to isolate specific molecules, such as cfDNA, from bodily fluids.

Owing to the various factors like, novel product launches, increasing demand for this segment and other facotrs help the kits and reagents segment is expected to grow during the forecast period. For instance, in February 2024, Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, launched the cfDNA Library Preparation Kit to enable liquid biopsy research.

Moreover, in October 2024, QIAGEN has announced significant updates to its sample technologies solutions for non-invasive liquid biopsy applications, aimed at research and clinical applications in oncology, prenatal care, and organ transplantation.

Geographical Analysis

North America is expected to hold a significant position in the Liquid Biopsy market

North America holds a substantial position in the liquid biopsy market and is expected to hold most of the market due to novel tests innovations, advanced healthcare infrastructure, high cancer prevalence, and investment in precision medicine. For instance, in July 2024, Guardant Health, Inc., a leading precision oncology company, announced the launch of a major upgrade to its market-leading Guardant360 liquid biopsy test. The new enhanced test evaluates biomarkers in 739 genes in total, which is 10 times more cancer biomarkers than the previous version of Guardant360 evaluated. The test can also identify an extensive array of emerging biomarkers to precisely characterize cancer and can quantify disease burden at much higher sensitivity.

Moreover, the rising incidence of cancer in the U.S. and Canada drives demand for early, non-invasive diagnostic solutions. FDA regulatory support and increased cancer research funding accelerate the development of liquid biopsy technologies. Leading biotechnology and pharmaceutical companies and collaborations in biomarker research and clinical trials further strengthen North America's market growth.

Competitive Landscape

The major global players in the liquid biopsy market include Exosome Sciences Inc., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, Qiagen, BioChain Institute Inc., Sysmex Europe SE, Eurofins Genomics, and Goffin Molecular Technologies among others.

Key Developments

• In February 2025, SOPHiA GENETICS, a leader in AI healthcare technology and data-driven medicine, has achieved a milestone in the global adoption of its cancer testing applications MSK-ACCESS powered with SOPHiA DDM and MSK-IMPACT powered with SOPHiA DDM. 37 prominent institutions, including top researchers and opinion leaders, have already adopted the Liquid Biopsy and Solid Tumor applications.
• In October 2024, GeneCentric Therapeutics has launched its EXpressCTSM liquid biopsy platform, allowing tissue RNA expression and epigenomics to be realized in liquid biopsy. The platform expands the application of the company's RNA-based gene expression signatures and diagnostic tests to cell-free DNA (cfDNA) liquid biopsy samples, including blood and urine.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

The global liquid biopsy market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Circulating Biomarker
• 3.3. Snippet by Application
• 3.4. Snippet by Technology
• 3.5. Snippet by End User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Cancer
    • 4.1.1.2. Rise in Customized Laser Surgery Based on Eye Biomechanics
  • 4.1.2. Restraints
    • 4.1.2.1. Standardization and Regulatory Challenges
    • 4.1.2.2. High Cost of Treatment Procedures
  • 4.1.3. Opportunity
    • 4.1.3.1. Expansion into Emerging Markets
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Pipeline Analysis
• 5.8. Supply Chain Analysis
• 5.9. Patent Analysis
• 5.10. SWOT Analysis
• 5.11. Unmet Needs and Gaps
• 5.12. Recommended Strategies for Market Entry and Expansion
• 5.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.14. Pricing Analysis and Price Dynamics
• 5.15. Key Opinion Leaders

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Kits & Reagents*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Instruments
• 6.4. Services

7. By Circulating Biomarker

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
  • 7.1.2. Market Attractiveness Index, By Circulating Biomarker
• 7.2. Circulating Tumor Cells*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Circulating Tumor DNA (ctDNA)
• 7.4. Cell-free DNA (cfDNA)
• 7.5. Extracellular Vesicles

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cancer Applications*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Non-Cancer Applications

9. By Technology

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.1.2. Market Attractiveness Index, By Technology
• 9.2. Multi-gene-parallel Analysis (NGS)*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Single Gene Analysis (PCR Microarrays)

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospitals and Physician Laboratories*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Research Centers
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. Latin America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Mexico
    • 11.4.8.2. Brazil
    • 11.4.8.3. Argentina
    • 11.4.8.4. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

Key Market Players

• 13.1. Exosome Sciences Inc*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio
    • 13.1.2.1. Product Description
    • 13.1.2.2. Product Key Performance Indicators (KPIs)
    • 13.1.2.3. Historic and Forecasted Product Sales
    • 13.1.2.4. Product Sales Volume
  • 13.1.3. Financial Overview
    • 13.1.3.1. Company Revenue's
    • 13.1.3.2. Geographical Revenue Shares
    • 13.1.3.3. Revenue Forecasts
  • 13.1.4. Key Developments
    • 13.1.4.1. Mergers & Acquisitions
    • 13.1.4.2. Key Product Development Activities
    • 13.1.4.3. Regulatory Approvals etc.
  • 13.1.5. SWOT Analysis
• 13.2. Illumina, Inc
• 13.3. Guardant Health
• 13.4. Thermo Fisher Scientific Inc
• 13.5. NeoGenomics Laboratories
• 13.6. Qiagen
• 13.7. BioChain Institute Inc
• 13.8. Sysmex Europe SE
• 13.9. Eurofins Genomics
• 13.10. Goffin Molecular Technologies
• Similar data will be provided for each market player.

Emerging Market Players

• 13.11. Exact Sciences*
  • 13.11.1. Pipeline Products Description
  • 13.11.2. Product Key Performance Indicators (KPIs)
  • 13.11.3. Key Activities
  • 13.11.4. Market Entry Timelines
  • 13.11.5. Product Penetration Rate
  • 13.11.6. Sales Estimation and Projections
• 13.12. Tempus
• 13.13. Dxcover Limited
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1 About Us and Services
• 12.2 Contact Us